Eckert & Ziegler SE (XTER:EUZ)

Q1 2026 Eckert & Ziegler SE Earnings Call Transcript

May 12, 2026 / 10:59 AM GMT

Release Date Price: €14.94 (-3.18%)

Transcript

Key Points

Positve

Eckert & Ziegler SE (XTER:EUZ) reported a 7% increase in overall sales, with a strong performance in the medical division, which grew by over 20%.
The company remains optimistic about the nuclear medicine field, expecting a 15% CAGR until 2030.
Eckert & Ziegler SE has a strong cash position of 120 million, providing flexibility for potential strategic investments.
The company has entered into a development partnership with Molecular Partners, enhancing its product pipeline.
Eckert & Ziegler SE is expanding its market presence, with new products and increased sales in key regions like North and South America, Europe, and Asia.

Negative

The isotope segment experienced a 7% decline in revenue compared to the previous year, impacted by currency fluctuations.
The company faced challenges in the first quarter due to a weak US dollar, affecting FX-adjusted revenues.
There was a notable decrease in service revenue, partly due to the absence of a significant license deal this year.
The IP segment had a slow start to the year, with lower performance in areas like oil well logging and isotope sales.
Despite a strong cash position, the company has not announced any immediate plans for acquisitions or share buybacks, which may concern some investors looking for aggressive growth strategies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EUZG.DE - Eckert & Ziegler SE
Q1 2026 Eckert & Ziegler SE Earnings Call
May 12, 2026 / NTS GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, this is Harald Hasselmann, CEO of Eckert and Siegler speaking. Very much welcome. Good morning and good afternoon. I'm speaking out of Berlin and together with my colleagues, Caroline, Olivier and Julian, whom you all know pretty well, we are going to lead you through the Q1 results, followed by Q&A session.

My presentation. Which will last for the first half of today's meeting, will be recorded. So for those who cannot participate, you are able to listen to once thereafter, whereas the Q&A session is a live session only.

So in a nutshell, the Q1 result of 2026 confirms that our strategy is in line and that our numbers are on track.

By that, we are also confirming our

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.